Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified |
| |
Authors: | Agustin Avilés Claudia Castañeda Natividad Neri Sergio Cleto Alejandra Talavera Martha González Judith Huerta-Guzmán M. Jesús Nambo |
| |
Affiliation: | (1) Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico;(2) Plaza Luis Cabrera 5-502, Colonia Roma, Mexico, DF, 06700, Mexico;(3) Department of Hematology, Oncology Hospital, National Medical Center, IMSS, Mexico, DF, Mexico |
| |
Abstract: | We performed a controlled clinical trial to define the use of a brief therapy: CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone) compared with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of peripheral T-cell lymphoma unspecific (PTCLu). The end point to the study was to assess efficacy, measured from complete response rate (CRR), progression-free survival (PFS), and overall survival in 217 previously untreated patients with PTCLu. In an intent-to treat analysis all patients were evaluable. CRR was 76% in CMED regimen and 57% in CHOP arm (P < 0.05); actuarial curves at 10 years showed that PFS was 70% and 43%, respectively (P < 0.01); overall survival was 60% and 34%, respectively (P < 0.01). Adjuvant radiotherapy was employed in 48 cases (54% of patients who achieve CR in CMED arm) and 30 patients (47% of patients who achieve CR in CHOP arm). Acute toxicity was mild and well tolerated. Our results showed that the CMED regimen is feasible and effective in PTCLu. |
| |
Keywords: | Malignant lymphoma T-cell lymphoma Chemotherapy Prognostic factors |
本文献已被 PubMed SpringerLink 等数据库收录! |
|